BRIEF-Additional data analyses from phase IIb trial of MIN-101 in schizophrenia underscore benefit in multiple measurements of cognitive function

* Additional data analyses from phase IIb trial of MIN-101

in schizophrenia underscore benefit in multiple measurements of

cognitive function

Source text for Eikon:

Further company coverage:

Read more